相似文献
1
Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician.癌症治疗相关的心脏功能障碍：临床医生概述
Clin Med Insights Cardiol. 2019 Jul 29;13:1179546819866445. doi: 10.1177/1179546819866445. eCollection 2019.
2
Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?非蒽环类化疗药物所致癌症治疗相关心脏功能障碍：证据有哪些？
JACC CardioOncol. 2019 Dec 17;1(2):280-290. doi: 10.1016/j.jaccao.2019.09.007. eCollection 2019 Dec.
3
[Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach].[癌症化疗的心脏毒性——机制与治疗方法]
Gan To Kagaku Ryoho. 2017 Dec;44(13):2058-2063.
4
Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction.检测早期癌症治疗相关心脏功能障碍的生物标志物研究进展。
Front Cardiovasc Med. 2021 Nov 10;8:753313. doi: 10.3389/fcvm.2021.753313. eCollection 2021.
5
[Prevention and Treatment of Cancer Therapeutics-related Cardiac Dysfunction].癌症治疗相关心脏功能障碍的防治
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Dec 30;41(6):842-850. doi: 10.3881/j.issn.1000-503X.11380.
6
Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.心室-动脉耦合和圆周应变的非侵入性测量可预测癌症治疗相关的心脏功能障碍。
JACC Cardiovasc Imaging. 2016 Oct;9(10):1131-1141. doi: 10.1016/j.jcmg.2015.11.024. Epub 2016 Apr 13.
7
Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.基线免疫球蛋白E水平作为多柔比星和曲妥珠单抗相关心脏功能障碍的标志物
Circ Res. 2016 Oct 28;119(10):1135-1144. doi: 10.1161/CIRCRESAHA.116.309004. Epub 2016 Aug 31.
8
Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy.超声心动图在癌症治疗期间和治疗后患者临床决策中的当代作用。
JACC Cardiovasc Imaging. 2018 Aug;11(8):1122-1131. doi: 10.1016/j.jcmg.2018.03.025.
9
Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience.新冠疫情时代癌症治疗相关心脏功能障碍的更高发病率：一家心脏肿瘤中心的经验
J Cardiovasc Dev Dis. 2023 Jan 6;10(1):23. doi: 10.3390/jcdd10010023.
10
Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.心脏肿瘤学：一种用于癌症患者心脏功能障碍检测、预防和管理的多学科方法。
Jpn J Clin Oncol. 2017 Aug 1;47(8):678-682. doi: 10.1093/jjco/hyx068.
引用本文的文献
1
Coronary microvascular dysfunction: a review of its association with extracardiac organ pathologies.冠状动脉微血管功能障碍：其与心外器官病理状况相关性的综述
Front Cardiovasc Med. 2025 Aug 13;12:1616332. doi: 10.3389/fcvm.2025.1616332. eCollection 2025.
2
Anthracyclines induce global changes in cardiomyocyte chromatin accessibility that overlap with cardiovascular disease loci.蒽环类药物可诱导心肌细胞染色质可及性发生全局性变化，这些变化与心血管疾病相关基因座重叠。
bioRxiv. 2025 Jun 16:2025.06.11.658997. doi: 10.1101/2025.06.11.658997.
3
Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update.阿霉素诱导的心脏毒性：全面更新
J Cardiovasc Dev Dis. 2025 May 30;12(6):207. doi: 10.3390/jcdd12060207.
4
Non-cancer effects after proton beam therapy for pediatric tumors- a narrative review.质子束治疗小儿肿瘤后的非癌症效应——一项叙述性综述。
Front Oncol. 2025 May 30;15:1554765. doi: 10.3389/fonc.2025.1554765. eCollection 2025.
5
Unraveling the genetic blueprint of doxorubicin-induced cardiotoxicity through systems genetics approaches.通过系统遗传学方法解析阿霉素诱导的心脏毒性的遗传蓝图。
Cardiooncology. 2025 Jun 3;11(1):53. doi: 10.1186/s40959-025-00349-y.
6
Dynamic expression of the myocardial sigma-1 receptor after doxorubicin cardiomyopathy using radioiodine-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5 V) imaging.使用放射性碘标记的2-[4-(2-碘苯基)哌啶基]环戊醇（OI5 V）成像研究阿霉素心肌病后心肌σ-1受体的动态表达。
Ann Nucl Med. 2025 May 29. doi: 10.1007/s12149-025-02062-3.
7
Cardio-Oncology Challenges in Elderly Patients.老年患者的心脏肿瘤学挑战
J Clin Med. 2025 May 7;14(9):3257. doi: 10.3390/jcm14093257.
8
Unraveling the Genetic Blueprint of Doxorubicin-Induced Cardiotoxicity Through Systems Genetics Approaches.通过系统遗传学方法解析阿霉素诱导的心脏毒性的遗传蓝图。
Res Sq. 2025 Apr 15:rs.3.rs-6224399. doi: 10.21203/rs.3.rs-6224399/v1.
9
Effect of cyclophospamide, doxorubicin, vincristine and prednisone/prednisolone (CHOP) chemotherapy regimens on left ventricular systolic function and cardiac structural abnormalities in non-Hodgkin lymphoma patients.环磷酰胺、阿霉素、长春新碱和泼尼松/泼尼松龙（CHOP）化疗方案对非霍奇金淋巴瘤患者左心室收缩功能及心脏结构异常的影响。
J Egypt Natl Canc Inst. 2025 May 1;37(1):29. doi: 10.1186/s43046-025-00288-w.
10
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility.接受BRAF/MEK抑制剂治疗的转移性黑色素瘤患者的心脏毒性：发病率、危险因素及可逆性的真实世界分析
Acta Oncol. 2025 Apr 13;64:507-515. doi: 10.2340/1651-226X.2025.42567.
本文引用的文献
1
hiPSCs in cardio-oncology: deciphering the genomics.心肌肿瘤学中的诱导多能干细胞：解析基因组学。
Cardiovasc Res. 2019 Apr 15;115(5):935-948. doi: 10.1093/cvr/cvz018.
2
Cardio-oncology: an overview on outpatient management and future developments.心脏肿瘤学：门诊管理与未来发展概述
Neth Heart J. 2018 Nov;26(11):521-532. doi: 10.1007/s12471-018-1148-7.
3
Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.精准心脏肿瘤学：了解癌症治疗的心脏毒性
NPJ Precis Oncol. 2017 Sep 12;1(1):31. doi: 10.1038/s41698-017-0034-x. eCollection 2017.
4
Immune Checkpoint Inhibitor-Associated Myocarditis.免疫检查点抑制剂相关性心肌炎。
Oncologist. 2018 Aug;23(8):879-886. doi: 10.1634/theoncologist.2018-0130. Epub 2018 May 25.
5
Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data.乳腺癌放疗后的心脏结构损伤：个体患者数据的横断面研究。
J Clin Oncol. 2018 Aug 1;36(22):2288-2296. doi: 10.1200/JCO.2017.77.6351. Epub 2018 May 23.
6
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
7
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.卡维地洛预防化疗相关性心脏毒性：CECCY 试验。
J Am Coll Cardiol. 2018 May 22;71(20):2281-2290. doi: 10.1016/j.jacc.2018.02.049. Epub 2018 Mar 11.
8
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关致死性心肌炎报告增加。
Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.
9
Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.系统药理学分析选定的酪氨酸激酶抑制剂引起的线粒体心脏毒性。
J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):401-418. doi: 10.1007/s10928-018-9578-9. Epub 2018 Feb 14.
10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
Zotero 插件